Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure
European Heart Journal - Cardiovascular Pharmacotherapy · 2025
DOI: 10.1093/ehjcvp/pvae091 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Marianne Reimers-Wessberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels allé 8, 171 77 Stockholm…. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Alzheimer Disease, Heart Failure, Hospitalization. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stockholm County Council, Karolinska Institutet, Swedish Medical Research Council.
Themen: Herzinsuffizienz, Demenz
Abstract (Originalsprache)
Aims
Cholinesterase inhibitors (ChEIs) have beneficial effects on the heart. Associations between ChEI-use and reduced mortality and cardiovascular events in Alzheimer's disease (AD) have been shown. Whether these associations exist in those with both heart failure (HF) and AD is unknown. Methods and results A propensity score (PS) matched cohort with patients with HF and AD was obtained through linking registers for cognitive/dementia disorders, comorbidities, drug prescription, and death, in Sweden, to analyse associations between ChEI-use and risk of mortality or hospitalization for HF, stroke, or myocardial infarction, were examined. In 455 patients with and 455 without ChEI treatment, ChEI use was associated with reductions of mortality and hospitalization due to HF by 21% [0.79; (confidence interval) CI 0.66–0.96] and 47% (0.53; CI 0.38–0.75), respectively. Donepezil and galantamine but not rivastigmine were associated with a lower risk of death compared with non-users. Donepezil was associated with a lower risk of hospitalization due to HF compared with non-users. There was no significant difference in hospitalization for bradycardia, AV block, or implantation of pacemaker between ChEI use and non-use.
Conclusion
This study suggests that in persons with HF and AD, treatment with ChEIs is associated with improved survival and a decreased risk of hospital care for HF, but results due to the type of ChEI vary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels allé 8, 171 77 Stockholm, Sweden.
- Research and Development Unit, Stockholms Sjukhem, 112 19 Stockholm, Sweden.
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 171 65 Stockholm, Sweden.
- Theme Inflammation and Aging, Department of Aging, Karolinska University Hospital, 141 86 Stockholm, Sweden.
ORCID-Profile: Marianne Reimers-Wessberg, Hong Xu
Förderung
- Stockholm County Council
- Karolinska Institutet
- Swedish Medical Research Council
- Johanniterorden
- CIMED
Zitieren
APA
Reimers-Wessberg, M., Xu, H., Fastbom, J., Seiger, Å., & Eriksdotter, M. (2025). Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae091
Vancouver
Reimers-Wessberg M, Xu H, Fastbom J, Seiger Å, Eriksdotter M. Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae091
BibTeX
@article{ReimersWessberg2025,
author = {Reimers-Wessberg, Marianne and Xu, Hong and Fastbom, Johan and Seiger, Åke and Eriksdotter, Maria},
title = {Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
doi = {10.1093/ehjcvp/pvae091}
}
EUVIMED